GLP-one receptor agonists like Semaglutide and Tirzepatide have demonstrated substantial cardiovascular Advantages, including lessened possibility of main adverse cardiovascular activities (MACE) such as coronary heart attack and stroke44. Kidney harm Acute kidney injury and worsening of Long-term renal failure, which may often call for hemo